%PDF-1.4
%
39 0 obj
<>
endobj
36 0 obj
<>
endobj
84 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-07T16:32:25Z
2024-03-28T11:50:34-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T11:50:34-07:00
application/pdf
Heather
2003-512.dec.suppl 68
uuid:9376c748-1dd2-11b2-0a00-e609278d5b00
uuid:9376c74b-1dd2-11b2-0a00-1e0000000000
endstream
endobj
25 0 obj
<>
endobj
26 0 obj
<>
endobj
40 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 13 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
98 0 obj
[102 0 R]
endobj
99 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 10 0 0 10 157.3333 713.1616 Tm
(SHERINE GABRIEL, )Tj
/T1_1 1 Tf
6 0 0 6 256.454 713.1616 Tm
(MD, MSc,)Tj
8 0 0 8 157.3333 703.1616 Tm
(Department of Health Services Research )Tj
0 -1.25 TD
[(and Division of Rheumatology)64.8 (,)]TJ
T*
(Department of Internal Medicine,)Tj
T*
(Mayo Clinic,)Tj
T*
[(Rochester)39.7 (, Minnesota, USA.)]TJ
/T1_0 1 Tf
0 Tw 10 0 0 10 54 639.1616 Tm
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
-0.0313 Tw 8 0 0 8 54 629.1616 Tm
(This conference was supported in part by a grant from the National Insti\
tute)Tj
0.18311 Tw T*
[(of )54.8 (Arthritis and Musculoskeletal and Skin Diseases and by unrestricted)]TJ
0.00169 Tc 0.3732 Tw T*
[(educational grants from )54.9 (Abbott Laboratories, )54.9 (AstraZeneca, Centocor)39.8 (,)]TJ
-0.00011 Tc 0.06731 Tw T*
[(McNeil, and Schering Plough \(International\) in accordance with )54.9 (ACCME)]TJ
0 Tw T*
(standards.)Tj
/T1_0 1 Tf
10 0 0 10 54 567.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 557.1616 Tm
[(1.)-875.1 (National Institute for Clinical Excellence. )17.7 (T)69.9 (echnical Guidance for)]TJ
1.675 -1.25 Td
(Manufacturers and Sponsors on Making a Submission to a)Tj
T*
[(T)69.9 (echnology )54.8 (Appraisal. www)64.9 (.nice.or)17.7 (g.uk \(T)69.7 (echnology )54.8 (Appraisals\))]TJ
T*
[([W)79.8 (orld )17.8 (W)39.8 (ide )17.8 (W)79.9 (eb]. March 2001. Cited: July 15, 2003. )54.9 (A)73.9 (vailable)]TJ
T*
[(from: www)64.9 (.nice.or)17.7 (g.uk \(T)69.7 (echnology )54.8 (Appraisals\).)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Department of Health and Community Services )54.8 (AGPS.)]TJ
1.675 -1.25 Td
[(Commonwealth of )54.8 (Australia Guidelines for the Pharmaceutical)]TJ
T*
(Industry on Preparation of Submissions to the Pharmaceutical)Tj
T*
[(Benefits )54.8 (Advisory Committee: Including Economic )54.8 (Analyses.)]TJ
T*
[(Canberra: Department of Health and Community Services )54.8 (AGPS;)]TJ
0 Tc 0 Tw T*
(1995.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Gold MR, Siegel JE, Russell LB, )17.7 (W)79.9 (einstein MC. Cost-ef)17.7 (fectiveness)]TJ
1.675 -1.25 Td
[(in health and medicine. )17.7 (V)128.9 (ol II. New )36.8 (Y)99.8 (ork, NY)91.7 (: Oxford University)]TJ
T*
(Press, Inc.; 1996.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Canadian Coordinating Of)17.7 (fice for Health )17.7 (T)69.9 (echnology )54.8 (Assessment)]TJ
1.675 -1.25 Td
[(\(CCOHT)79.7 (A\). Guidelines for economic evaluation of )]TJ
T*
(pharmaceuticals. 2nd ed. Ottawa; 1997.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Murray CJ, Evans DB, )54.8 (Acharya )54.8 (A, Baltussen RM. Development of)]TJ
1.675 -1.25 Td
[(WHO guidelines on generalized cost-ef)17.7 (fectiveness analysis. Health)]TJ
0 Tc T*
(Econ 2000;9:235-51.)Tj
-0.00011 Tc 31.325 43.421 Td
[(6.)-875.1 (Gabriel SE. Controversies in economic evaluation in the rheumatic)]TJ
1.675 -1.25 Td
(diseases [editorial; comment]. J Rheumatol 1999;26:1859-60.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (O\325Brien B. Statistical analysis of cost ef)17.7 (fectiveness data. J)]TJ
1.675 -1.25 Td
(Rheumatol 1999;26:2078-80.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Guillemin F)79.7 (.)-0.1 ( )17.7 (The value of utility: assumptions underlying )]TJ
1.675 -1.25 Td
(preferences and quality adjusted life years [editorial] [see)Tj
T*
(comments]. J Rheumatol 1999;26:1861-63.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Maetzel )54.8 (A, Bombardier C. Give observational studies a chance:)]TJ
1.675 -1.25 Td
(Better observational studies make better economic evaluations. )Tj
T*
(J Rheumatol 1999;26:2298-9.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Cranney )54.8 (A, Coyle D, )17.7 (W)79.9 (elch )17.7 (V)128.9 (, Lee K, )17.7 (T)35 (ugwell P)110.7 (. Current )]TJ
2.175 -1.25 Td
[(controversies in cost ef)17.7 (fectiveness analysis of osteoporosis )]TJ
T*
(therapies. J Rheumatol 1999;26:2300-2.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Ruf)17.7 (f B. OMERACT)49.7 (: Economic evaluations and health policy)64.8 (. )]TJ
2.1381 -1.25 Td
(J Rheumatol 1999;26:2076-7.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Gabriel SE, )17.7 (T)35 (ugwell P)110.7 (, O\325Brien B, et al. Report of the OMERACT)]TJ
2.175 -1.25 Td
[(T)69.9 (ask Force on Economic Evaluation. J Rheumatol 1999;26:203-6.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Gabriel SE. OMERACT)-257.3 (5 Economics )17.7 (W)79.9 (orking Group report:)]TJ
2.175 -1.25 Td
(Introduction. J Rheumatol 2001;28:640-1.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Gabriel SE, Drummond MF)79.7 (, Coyle D, et al. OMERACT)]TJ
2.175 -1.25 Td
[(5 \321 Economics )17.7 (W)79.9 (orking Group: summary)64.8 (, recommendations, and)]TJ
T*
(research agenda. J Rheumatol 2001;28:670-3.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Gabriel S, Drummond M, Maetzel )54.8 (A, et al. OMERACT)-257.3 (6)]TJ
2.175 -1.25 Td
[(Economics )17.7 (W)79.9 (orking Group report: )54.8 (A)-220.1 (proposal for a reference case)]TJ
T*
(for economic evaluation in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:886-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Coyle D, )17.7 (T)69.9 (osteson )54.8 (ANA. )17.7 (T)69.9 (owards a reference case for economic)]TJ
2.175 -1.25 Td
(evaluation of osteoporosis treatments. J Rheumatol 2003;30 Suppl)Tj
0 Tw T*
(68:31-6.)Tj
0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Drummond M, Maetzel )54.8 (A, Gabriel SE, March LM. )17.7 (T)69.9 (owards a)]TJ
2.175 -1.25 Td
(reference case for use in future economic evaluations of)Tj
T*
(interventions in osteoarthritis. J Rheumatol 2003;30 )Tj
0 Tc T*
(Suppl 68:26-30.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 8 0 0 8 354.2144 35.9844 Tm
[(The Journal of Rheumatology 2003, V)110.7 (olume 30, Supplement 68)]TJ
0 Tc 0 Tw -37.5268 -0.0313 Td
(4)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
19 0 obj
<>stream
8;Z\7Mf-Et#ikr7OPa3Q?jrAHQUeN!&scQMadiIm,HY^UnUD^#CnL:0nseB@>k`]9
DXFtk1PsrdhCTkY-$$qWbos!lh,;p>QW-D(e#DE8`%nh;FQD/>TI.TS]3K=nfiX28
*3gm;1(S!-WB-7!19h>4f]j%;Gs(+r!'1g3&qiW-K9UTYF]'\N0]IM`f/XO]kPKM6#&/(3e^X+$-68P%
UPK),o,9Vie[W5q:OHrZOdk06;n%M&(f'<"+tWE]^dJ-a"omJX32s/RkQg&2m,#3]
:r/fhE2:MeA14YlWu>fOM)=P;TEV%9R6g4:d)63TOhHVNhGVVHHk
0pac2-'f4]\X%l$cKCj4o$`NZRFYTbFFAM/1H
UX'K2&cW,$l#-E,C:s'o!,<.'+T~>
endstream
endobj
23 0 obj
[/Indexed/DeviceRGB 255 22 0 R]
endobj
22 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
10 0 obj
<>
endobj
42 0 obj
<>
endobj
45 0 obj
<>
endobj
75 0 obj
<>
endobj
89 0 obj
<>
endobj
43 0 obj
<>
endobj
67 0 obj
<>stream
H|S{PSgp+bW(
ehj-,*HB0 $!HBȃDg@Ap ߠT*눂2Zvt7?:sf|s9!(.u۶ȕ!Oj.H~b!ZFШO'zt؞z(g`CYQdwyʼEq'4аMLXO+OO|WF(G%RPBnH3Eb
&ɍ\ )Ix,W-cR !9Tq)J!"s[LL+t7WbL{Hdac^Q|~gϓ-ZdLљWqMԜ|cfPhίM--L+ڥla$7?/+ͷj7KKVUfd2Q SoB_ Hq.!'-).:MˎG8[uh}CWf'3>!J6DA#beE2"CÔl:6=|3+,l@!JpchMF cIZ,=ʆ\+/|;K-}Z6>u
Q}bo |ͷw3x6 Pڒ2niaD`]d|,
@1rGG4M$̍glֲɊ, zwBŕSJsJ*JB%QvSvo{Omw7Nڟ/ȅĩ@eFQjaĶ,Mѱ"}/|1A9jL!/~nƾt(L8h`<Ř&jI 5Mw ᎄ5?\읮:\YtC k!.+<9ĉ~^:G+:Vݢz6&Gu
T7:ؼn
N}^
΅DP`x`##{p1 WQy<Q?po$uy8#6zB${vk4[@N^ziqeؽ^W-}M[>Nc,Δf~}2=%<O}0)T,=9Ky